文献速递痛风与晶体性关节病

别嘌醇剂量递增达标治疗痛风随机对照试验

A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
PubMed 文献 · Ann Rheum Dis · 2017-03-17

该随机对照试验纳入183例血尿酸≥6 mg/dL的痛风患者,比较继续原剂量与按月递增别嘌醇至血尿酸<6 mg/dL的疗效与安全性。12个月时递增组血尿酸降幅更大,达标率更高,不良事件与死亡无组间差异,提示高于肌酐清除率对应剂量的别嘌醇可有效且耐受良好地降尿酸。

要点

  • 别嘌醇按月递增至血尿酸<6 mg/dL可显著降低血尿酸。
  • 递增组12个月达标率69%,对照组32%,组间差异显著。
  • 严重不良事件与死亡无组间差异,仅1例可能与别嘌醇相关。

核心结论

  • 高于肌酐清除率对应剂量的别嘌醇可有效将多数痛风患者血尿酸降至治疗目标。
  • 别嘌醇剂量递增耐受良好,未增加严重不良事件或死亡风险。

研究设计与样本

  • 随机、对照、平行组比较临床试验,纳入接受至少肌酐清除率对应别嘌醇剂量≥1个月且血尿酸≥6 mg/dL的痛风患者。
  • 183例参与者随机分为继续当前剂量组(对照,93例)和别嘌醇剂量递增组(90例),疗程12个月。
  • 递增组每月增加别嘌醇剂量直至血尿酸<6 mg/dL。

主要发现

  • 基线平均(SD)血尿酸为7.15(1.6)mg/dL,别嘌醇剂量269 mg/天,52%患者肌酐清除率<60 mL/min。
  • 末次访视血尿酸平均变化:对照组-0.34 mg/dL,递增组-1.5 mg/dL(p<0.001),平均差异1.2 mg/dL(95%CI 0.67至1.5,p<0.001)。
  • 第12个月血尿酸<6 mg/dL比例:对照组32%,递增组69%。
  • 严重不良事件:对照组25例共43次,递增组22例共35次;仅1次被认为可能与别嘌醇相关。
  • 对照组和递增组各5例死亡,均认为与别嘌醇无关;两组肝功能轻度升高常见,少数γ-谷氨酰转移酶中度升高,肾功能变化无组间差异。

关键数值与推荐

  • 主要终点为血尿酸降低和不良事件。
  • 递增组以血尿酸<6 mg/dL为治疗目标,每月调整剂量。

临床怎么用

  • 对接受肌酐清除率对应别嘌醇剂量后血尿酸仍≥6 mg/dL的痛风患者,可考虑按月递增别嘌醇剂量以达到血尿酸<6 mg/dL。
  • 递增过程中需监测不良事件,但严重不良事件风险未见显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the efficacy and safety of allopurinol dose escalation using a treat-to-target serum urate (SU) approach. METHODS: A randomised, controlled, parallel-group, comparative clinical trial was undertaken. People with gout receiving at least creatinine clearance (CrCL)-based allopurinol dose for ≥1 month and SU ≥6 mg/dL were recruited. Participants were randomised to continue current dose (control) or allopurinol dose escalation for 12 months. In the dose escalation group, allopurinol was increased monthly until SU was <6 mg/dL. The primary endpoints were reduction in SU and adverse events (AEs). RESULTS: 183 participants (93 control, 90 dose escalation) were recruited. At baseline, mean (SD) urate was 7.15 (1.6) mg/dL and allopurinol dose 269 mg/day. 52% had CrCL<60 mL/min. Mean changes in SU at the final visit were -0.34 mg/dL in the control group and -1.5 mg/dL in the dose escalation group (p<0.001) with a mean difference of 1.2 mg/dL (95% CI 0.67 to 1.5, p<0.001). At month 12, 32% of controls and 69% in the dose escalation had SU <6 mg/dL. There were 43 serious AEs in 25 controls and 35 events in 22 dose escalation participants. Only one was considered probably related to allopurinol. Five control and five dose escalation participants died; none was considered allopurinol related. Mild elevations in LFTs were common in both groups, a few moderate increases in gamma glutamyl transferase (GGT) were noted. There was no difference in renal function changes between randomised groups. CONCLUSIONS: Higher than CrCL-based doses of allopurinol can effectively lower SU to treatment target in most people with gout. Allopurinol dose escalation is well tolerated. TRIAL REGISTRATION NUMBER: ANZCTR12611000845932; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017. PMID: 28314755. doi:10.1136/annrheumdis-2016-210872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。